European Medicines Agency awards PRIME status to ADP-A2M4 for treatment of synovial sarcoma

The decision provides the company with enhanced scientific and regulatory support to accelerate the development of this adoptive T-cell therapy and potentially patient access to a novel therapy where there is significant unmet need.

Source:

PharmaTimes